Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Role of protein phosphatases in the cancer microenvironment.

Ruvolo PP.

Biochim Biophys Acta. 2018 Jul 17. pii: S0167-4889(18)30166-6. doi: 10.1016/j.bbamcr.2018.07.006. [Epub ahead of print] Review.

PMID:
30026077
2.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158. [Epub ahead of print]

PMID:
29741984
3.

Behind the Robot's Smiles and Frowns: In Social Context, People Do Not Mirror Android's Expressions But React to Their Informational Value.

Hofree G, Ruvolo P, Reinert A, Bartlett MS, Winkielman P.

Front Neurorobot. 2018 Apr 24;12:14. doi: 10.3389/fnbot.2018.00014. eCollection 2018.

4.

Role of MSC-derived galectin 3 in the AML microenvironment.

Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N Jr, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M.

Biochim Biophys Acta. 2018 Jul;1865(7):959-969. doi: 10.1016/j.bbamcr.2018.04.005. Epub 2018 Apr 12.

PMID:
29655803
5.

Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival.

Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N Jr, Konopleva M, Andreeff M.

Haematologica. 2018 May;103(5):810-821. doi: 10.3324/haematol.2017.172429. Epub 2018 Mar 15.

6.

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.

Clin Cancer Res. 2018 May 15;24(10):2417-2429. doi: 10.1158/1078-0432.CCR-17-1556. Epub 2018 Feb 20.

PMID:
29463558
7.

The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.

Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K.

Front Immunol. 2018 Jan 15;8:1773. doi: 10.3389/fimmu.2017.01773. eCollection 2017.

8.

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.

Steelman LS, Abrams SL, Ruvolo P, Ruvolo V, Cocco L, Ratti S, Martelli AM, Neri LM, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Dec 6;8(68):113013-113033. doi: 10.18632/oncotarget.22956. eCollection 2017 Dec 22.

9.

Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia.

Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M.

Oncotarget. 2017 Jul 6;8(48):83354-83369. doi: 10.18632/oncotarget.19042. eCollection 2017 Oct 13.

10.

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Aug 24;8(44):76525-76557. doi: 10.18632/oncotarget.20408. eCollection 2017 Sep 29.

11.

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.

Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M.

Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.

12.

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.

Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM.

Haematologica. 2017 Dec;102(12):2048-2057. doi: 10.3324/haematol.2017.168856. Epub 2017 Sep 14.

13.

GSK-3 as a novel prognostic indicator in leukemia.

Ruvolo PP.

Adv Biol Regul. 2017 Aug;65:26-35. doi: 10.1016/j.jbior.2017.05.001. Epub 2017 May 8. Review.

PMID:
28499784
14.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

15.

Editorial: The Emerging Role for PP2A in Hematologic Malignancies.

Ruvolo PP.

Front Oncol. 2016 Aug 31;6:195. doi: 10.3389/fonc.2016.00195. eCollection 2016. No abstract available.

16.

The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance.

Ruvolo PP.

BBA Clin. 2016 Aug 3;6:87-99. doi: 10.1016/j.bbacli.2016.08.002. eCollection 2016 Dec. Review.

17.

Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.

Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M, Ogretmen B.

Blood. 2016 Oct 13;128(15):1944-1958. Epub 2016 Aug 18.

18.

Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.

Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N Jr, Kantarjian H, Andreeff M, Borthakur G.

Blood. 2016 Sep 1;128(9):1260-9. doi: 10.1182/blood-2016-01-692244. Epub 2016 Jun 7.

19.

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.

Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M.

Sci Signal. 2016 Feb 16;9(415):ra17. doi: 10.1126/scisignal.aac4380.

20.

Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance.

Semenza GL, Ruvolo PP.

Biochim Biophys Acta. 2016 Mar;1863(3):379-381. doi: 10.1016/j.bbamcr.2015.12.015. Epub 2015 Dec 23. No abstract available.

21.

Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.

Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N Jr, Davis RE, Andreeff M.

Biochim Biophys Acta. 2016 Apr;1863(4):562-71. doi: 10.1016/j.bbamcr.2015.12.008. Epub 2015 Dec 17.

22.

Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.

Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N Jr, Borthakur G, Konopleva M, Andreeff M, Kornblau SM.

BBA Clin. 2015 Jul 23;4:59-68. doi: 10.1016/j.bbacli.2015.07.001. eCollection 2015 Dec.

23.

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.

Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M.

PLoS One. 2015 Oct 6;10(10):e0139254. doi: 10.1371/journal.pone.0139254. eCollection 2015.

24.

Infants Time Their Smiles to Make Their Moms Smile.

Ruvolo P, Messinger D, Movellan J.

PLoS One. 2015 Sep 23;10(9):e0136492. doi: 10.1371/journal.pone.0136492. eCollection 2015.

25.

Galectin 3 as a guardian of the tumor microenvironment.

Ruvolo PP.

Biochim Biophys Acta. 2016 Mar;1863(3):427-437. doi: 10.1016/j.bbamcr.2015.08.008. Epub 2015 Aug 8. Review.

26.

Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.

Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4.

27.

The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.

Lesyk G, Fong T, Ruvolo PP, Jurasz P.

J Thromb Haemost. 2015 Aug;13(8):1514-20. doi: 10.1111/jth.13010. Epub 2015 Jun 17.

28.

The Interplay between PP2A and microRNAs in Leukemia.

Ruvolo PP.

Front Oncol. 2015 Feb 20;5:43. doi: 10.3389/fonc.2015.00043. eCollection 2015. Review.

29.

Bridging the mechanical and the human mind: spontaneous mimicry of a physically present android.

Hofree G, Ruvolo P, Bartlett MS, Winkielman P.

PLoS One. 2014 Jul 18;9(7):e99934. doi: 10.1371/journal.pone.0099934. eCollection 2014.

30.

The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.

Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N Jr, Konopleva M, Calin G, Kornblau SM, Andreeff M.

Biochim Biophys Acta. 2014 Sep;1843(9):1969-77. doi: 10.1016/j.bbamcr.2014.05.006. Epub 2014 May 21.

31.

Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.

Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, Bueso-Ramos CE, Konoplev S, Davis RE, Konopleva M, Andreeff M.

Blood. 2014 Apr 24;123(17):2691-702. doi: 10.1182/blood-2013-06-511527. Epub 2014 Mar 5.

32.

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM.

Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28.

33.

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG.

Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.

34.

Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.

Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ.

Apoptosis. 2014 Apr;19(4):698-707. doi: 10.1007/s10495-013-0954-z.

35.

Pharmacologic protein kinase Cα inhibition uncouples human platelet-stimulated angiogenesis from collagen-induced aggregation.

Moncada de la Rosa C, Radziwon-Balicka A, El-Sikhry H, Seubert J, Ruvolo PP, Radomski MW, Jurasz P.

J Pharmacol Exp Ther. 2013 Apr;345(1):15-24. doi: 10.1124/jpet.112.200881. Epub 2013 Feb 5.

36.

The Herculean task of killing cancer cells: suppression of FOXO3A in acute leukemia involves a hydra of multiple survival kinases.

Ruvolo PP.

Cell Cycle. 2012 Jul 15;11(14):2589. doi: 10.4161/cc.21233. Epub 2012 Jul 15. No abstract available.

37.

Multilayer Architectures for Facial Action Unit Recognition.

Tingfan Wu, Butko NJ, Ruvolo P, Whitehill J, Bartlett MS, Movellan JR.

IEEE Trans Syst Man Cybern B Cybern. 2012 Aug;42(4):1027-38. doi: 10.1109/TSMCB.2012.2195170. Epub 2012 May 11.

PMID:
22588611
38.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.

Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.

39.

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.

Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM.

Leukemia. 2011 Nov;25(11):1711-7. doi: 10.1038/leu.2011.146. Epub 2011 Jun 10.

40.

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.

Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Review.

PMID:
21494257
41.

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA.

Leukemia. 2011 Jul;25(7):1064-79. doi: 10.1038/leu.2011.46. Epub 2011 Mar 25. Review.

PMID:
21436840
42.

Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.

Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M.

J Cell Biochem. 2011 Jun;112(6):1696-707. doi: 10.1002/jcb.23090.

43.

Human glycolipid transfer protein gene (GLTP) expression is regulated by Sp1 and Sp3: involvement of the bioactive sphingolipid ceramide.

Zou X, Gao Y, Ruvolo VR, Gardner TL, Ruvolo PP, Brown RE.

J Biol Chem. 2011 Jan 14;286(2):1301-11. doi: 10.1074/jbc.M110.127837. Epub 2010 Oct 25.

44.

Applying machine learning to infant interaction: the development is in the details.

Messinger DM, Ruvolo P, Ekas NV, Fogel A.

Neural Netw. 2010 Oct-Nov;23(8-9):1004-16. doi: 10.1016/j.neunet.2010.08.008. Epub 2010 Sep 21.

45.

Role for PKC δ in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.

Ruvolo VR, Karanjeet KB, Schuster TF, Brown R, Deng Y, Hinchcliffe E, Ruvolo PP.

J Signal Transduct. 2010 Jan 1;2010:584657.

46.

Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice.

Johnson TE, Kassie F, O'Sullivan MG, Negia M, Hanson TE, Upadhyaya P, Ruvolo PP, Hecht SS, Xing C.

Cancer Prev Res (Phila). 2008 Nov;1(6):430-8. doi: 10.1158/1940-6207.CAPR-08-0027.

47.

PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells.

Ruvolo VR, Kurinna SM, Karanjeet KB, Schuster TF, Martelli AM, McCubrey JA, Ruvolo PP.

J Biol Chem. 2008 Dec 19;283(51):35474-85. doi: 10.1074/jbc.M800951200. Epub 2008 Oct 28.

48.

Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.

Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, Konopleva M, Andreeff M, Radomski MW, Ruvolo PP.

Cell Cycle. 2008 Nov 1;7(21):3362-70. Epub 2008 Nov 2.

49.

Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.

Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner K Jr, Kondo S, Andreeff M, Konopleva M.

Mol Cancer Ther. 2008 May;7(5):1130-9. doi: 10.1158/1535-7163.MCT-07-0553.

50.

p21 activated kinase 5 activates Raf-1 and targets it to mitochondria.

Wu X, Carr HS, Dan I, Ruvolo PP, Frost JA.

J Cell Biochem. 2008 Sep 1;105(1):167-75. doi: 10.1002/jcb.21809.

Supplemental Content

Loading ...
Support Center